PE20212067A1 - Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada - Google Patents

Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada

Info

Publication number
PE20212067A1
PE20212067A1 PE2021001372A PE2021001372A PE20212067A1 PE 20212067 A1 PE20212067 A1 PE 20212067A1 PE 2021001372 A PE2021001372 A PE 2021001372A PE 2021001372 A PE2021001372 A PE 2021001372A PE 20212067 A1 PE20212067 A1 PE 20212067A1
Authority
PE
Peru
Prior art keywords
trifluoromethyl
crystalline form
dihydroisoquinolin
carboxamide
pyridin
Prior art date
Application number
PE2021001372A
Other languages
English (en)
Spanish (es)
Inventor
Carina Leys
Kristof Leonard Kimpe
Robert Michael Geertman
Haojuan Wei
Peng Zhou
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20212067A1 publication Critical patent/PE20212067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2021001372A 2019-02-22 2020-02-20 Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada PE20212067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (1)

Publication Number Publication Date
PE20212067A1 true PE20212067A1 (es) 2021-10-26

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001372A PE20212067A1 (es) 2019-02-22 2020-02-20 Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada

Country Status (21)

Country Link
US (1) US12269813B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927696B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523368A (cg-RX-API-DMAC7.html)
KR (1) KR20210131371A (cg-RX-API-DMAC7.html)
CN (1) CN113474339B (cg-RX-API-DMAC7.html)
AU (1) AU2020226723B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129623A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192320A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21067828A (cg-RX-API-DMAC7.html)
ES (1) ES2966132T3 (cg-RX-API-DMAC7.html)
IL (1) IL285675A (cg-RX-API-DMAC7.html)
JO (1) JOP20210227A1 (cg-RX-API-DMAC7.html)
MA (1) MA55019A (cg-RX-API-DMAC7.html)
MX (1) MX2021010133A (cg-RX-API-DMAC7.html)
PE (1) PE20212067A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552018A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108909SA (cg-RX-API-DMAC7.html)
TW (1) TW202045495A (cg-RX-API-DMAC7.html)
UY (1) UY38592A (cg-RX-API-DMAC7.html)
WO (1) WO2020169736A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
JP2023539729A (ja) 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
KR20230154227A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
WO2023016995A1 (en) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622571A4 (en) 2003-04-30 2012-05-02 Agensys Inc NUCLEIC ACIDS AND CORRESPONDING PROTEINS NAMED 109P1D4 FOR THE TREATMENT AND DETECTION OF CANCER
KR20090007347A (ko) * 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 c-MET 단백질 키나제 억제제
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2011161612A1 (en) 2010-06-22 2011-12-29 Basf Se Process for preparing 4-hydroxypyridines
JP6231085B2 (ja) * 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
MX2017001656A (es) 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
EP3374361A1 (en) 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
WO2017151786A1 (en) 2016-03-01 2017-09-08 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
EP3756268A1 (de) 2018-02-23 2020-12-30 Industrieanlagen-Betriebsgesellschaft mbH Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
JP2023539729A (ja) * 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤

Also Published As

Publication number Publication date
EA202192320A1 (ru) 2021-11-16
JOP20210227A1 (ar) 2021-08-18
EP3927696A1 (en) 2021-12-29
JP2022523368A (ja) 2022-04-22
EP3927696B1 (en) 2023-10-18
CN113474339A (zh) 2021-10-01
AU2020226723B2 (en) 2025-01-23
IL285675A (en) 2021-10-31
SG11202108909SA (en) 2021-09-29
TW202045495A (zh) 2020-12-16
CA3129623A1 (en) 2020-08-27
ES2966132T3 (es) 2024-04-18
AU2020226723A1 (en) 2021-08-19
US12269813B2 (en) 2025-04-08
UY38592A (es) 2020-08-31
BR112021016400A2 (pt) 2021-10-13
MA55019A (fr) 2021-12-29
EP3927696C0 (en) 2023-10-18
US20220127249A1 (en) 2022-04-28
KR20210131371A (ko) 2021-11-02
ECSP21067828A (es) 2021-11-18
MX2021010133A (es) 2021-09-23
CN113474339B (zh) 2025-02-25
PH12021552018A1 (en) 2022-09-19
WO2020169736A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
AR120703A1 (es) Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CL2019003619A1 (es) Preparación sólida para administración oral.
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
NZ627750A (en) Carbamate compounds and of making and using same
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2021010133A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada.
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.
EA202190452A1 (ru) Ингибиторы cdk8/19
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
MA38697A1 (fr) 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7
BRPI0413500A (pt) compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade